Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $21.96 USD
Change Today -0.47 / -2.10%
Volume 374.6K
MNTA On Other Exchanges
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (MNTA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/19/15 - $25.56
52 Week Low
10/13/14 - $9.38
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

momenta pharmaceuticals inc (MNTA) Related Businessweek News

No Related Businessweek News Found

momenta pharmaceuticals inc (MNTA) Details

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a complex drug consisting of a synthetic mixture of polypeptide chains for the treatment of patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923, a biosimilar for rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis; M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis; and other biosimilar programs. The company’s novel products comprise M402, a novel oncology drug candidate that is in a Phase 2 clinical study derived from heparin; hsIVIg program, a hyper-sialylated version of intravenous immunoglobulin; SIF3 program, a novel recombinant protein containing three IgG Fc regions joined to maximize activity; and Anti-FcRn program for acute and chronic/intermittent therapies in a range of autoantibody driven diseases. It has collaboration and license agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

256 Employees
Last Reported Date: 02/27/15
Founded in 2001

momenta pharmaceuticals inc (MNTA) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $643.4K
Co-Founder, Chief Scientific Officer and Seni...
Total Annual Compensation: $400.7K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $374.8K
Senior Vice President and President of Biosim...
Total Annual Compensation: $19.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.

momenta pharmaceuticals inc (MNTA) Key Developments

Momenta Pharmaceuticals Announces Executive Changes

Momenta Pharmaceuticals Inc. announced that Rick Shea has advised the company of his intention to step down as Chief Financial Officer (CFO) once a successor is identified and appointed. Mr. Shea will remain with the company to assist with the CFO succession and serve in a newly created role of Senior Vice President, Corporate Communications and Operations for a transition period prior to his planned retirement in 2016. Momenta has initiated a CFO search. Mr. Shea joined Momenta in October 2003 as Chief Financial Officer and Senior Vice President.

Momenta Pharmaceuticals, Inc. Announces Launch of Glatopa (Glatiramer Acetate Injection)

Momenta Pharmaceuticals Inc. announced that Sandoz has initiated its U.S. launch of once daily Glatopa (glatiramer acetate injection), a generic equivalent of daily COPAXONE 20 mg, developed under a collaboration agreement between Momenta and Sandoz. Glatopa is the first AP-rated substitutable generic indicated for the treatment of patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. Under the terms of its collaboration agreement with Sandoz, Momenta will receive a $10.0 million milestone payment upon first commercial sale. Momenta is also eligible to receive up to $120 million in remaining milestone payments upon the achievement of certain U.S. commercial and sales-based milestones for the Glatopa Glatopa was determined by the FDA to be therapeutically equivalent to daily COPAXONE 20 mg, with the same active ingredients, route of administration, strength and dosage form. Glatopa's high quality U.S.-based supply chain and manufacturing process meet rigid FDA standards, and Glatopa is fully substitutable at the pharmacy level. Sandoz has also introduced a patient support service offering that includes financial support to eligible patients, personalised injection training and 24-hour access to nurses to answer non-clinical questions.

Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE 20 mg Suit

Momenta Pharmaceuticals Inc. announced that the United States Court of Appeals for the Federal Circuit (CAFC) has again found that U.S. patent No. 5,800,808, related to a method of manufacturing glatiramer acetate, is invalid as indefinite.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $21.96 USD -0.47

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amarin Corp PLC $2.18 USD +0.03
Amphastar Pharmaceuticals Inc $15.83 USD -0.68
OraSure Technologies Inc $5.06 USD -0.18
SciClone Pharmaceuticals Inc $9.07 USD -0.295
Sucampo Pharmaceuticals Inc $21.39 USD -1.32
View Industry Companies

Industry Analysis


Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.4x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at